Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme
Enhanced quality of life: Losing weight with semaglutide can lead to increased energy levels, better mobility, and an overall improvement in physical and emotional well-being
Glossitis (inflamed tongue) usually resolves within two to three weeks, and patients report reduced oral discomfort
The USA is expected to record an 18.1% CAGR from 2026 to 2036 due to employer purchasing and direct-to-consumer access
US$ 21.09
US$ 20.16
US$ 26.88
